Arcam AB (publ) logo

ARCM BTA - Arcam AB (publ) News Story

SEK295 0.0  0.0%

Last Trade - 14/11/17

Sector
Industrials
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £66.2m
Position in Universe th / 1830

EUROPE RESEARCH ROUNDUP-GlaxoSmithKline, DIA, Roche

Fri 22nd July, 2016 6:02am
July 22 (Reuters) - Securities analysts revised their ratings and price targets on several 
European companies, including Norsk Hydro and Aegon, on Friday.  
     
    HIGHLIGHTS 
     * GlaxoSmithKline Plc  GSK.L : Leerink raises target price to 1,918p from 1,680p 
     * DIA  DIDA.MC : Jefferies raises to hold from underperform 
     * Roche  ROG.S : Bernstein cuts target price to Sfr 281 from Sfr 285 
       
Following is a summary of research actions on European companies reported by Reuters on Friday. 
Stock entries are in alphabetical order.   
     
     * Actelion Ltd  ATLN.S : Jefferies raises target price to Sfr 200 from Sfr 170 
     * Aegon NV  AEGN.AS : Jefferies cuts target price to 3.75 euros from 4.80 euros 
     * Altice NV  ATCA.AS : Citigroup cuts target price to 14 euros from 14.5 euros 
     * Arcam  ARCM.ST : Piper Jaffray cuts target price to Sek 155 from Sek 172 
     * Bouygues  BOUY.PA : Citigroup cuts target price to 27.3 euros 
     * DIA  DIDA.MC : Jefferies raises price target to 5.30 euros from 4.20 euros 
     * DIA  DIDA.MC : Jefferies raises to hold from underperform 
     * GlaxoSmithKline Plc  GSK.L : Leerink raises target price to 1,918p from 1,680p 
     * Norsk Hydro ASA  NHY.OL : Deutsche Bank raises target price to Nok 36.90 from Nok 34.80 
     * Numericable SFR  SFRGR.PA : Citigroup cuts target price to 23.5 euros from 32.5 euros   
     * Orange SA  ORAN.PA : Citigroup cuts target price to 17.5 euros; rating buy 
     * Roche  ROG.S : Bernstein cuts target price to Sfr 281 from Sfr 285 
  
 (Compiled by Tenzin Pema and Geetha Panchaksharam in Bengaluru) 
 ((Bengaluru Newsroom: +1 646 223 8780)) 
 
Keywords: RESEARCH EUROPE/
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.